Verona Pharma Ownership 2024 | Who Owns Verona Pharma Now?
Institutional Ownership
81.56%
Insider Ownership
3.90%
Retail Ownership
14.54%
Institutional Holders
129.00
Verona Pharma Institutional Shareholders
Institutional Shareholders by % of Total Shares
| Name | % Total Shares | % Total Assets | Current Shares | Change Amount | Change % | Market Value | Date |
|---|---|---|---|---|---|---|---|
| RA CAPITAL MANAGEMENT, L.P. | 9.46% | 1.46% | 7,632,646 | 1,314,656 | 20.81% | 110,368,061 | Jun 30, 2024 |
| NEA MANAGEMENT COMPANY, LLC | 6.92% | 6.08% | 5,584,753 | 476,190 | 9.32% | 80,755,528 | Jun 30, 2024 |
| DEEP TRACK CAPITAL, LP | 4.96% | 1.73% | 4,000,000 | 812,585 | 25.49% | 57,840,000 | Jun 30, 2024 |
| VIVO CAPITAL, LLC | 4.40% | 4.74% | 3,549,758 | -60,419 | -1.67% | 51,329,501 | Jun 30, 2024 |
| FRAZIER LIFE SCIENCES MANAGEMENT, L.P. | 4.11% | 2.24% | 3,314,349 | 300,000 | 9.95% | 47,925,487 | Jun 30, 2024 |
| MAVERICK CAPITAL LTD | 3.83% | 0.85% | 3,092,807 | 1,316,998 | 74.16% | 44,721,989 | Jun 30, 2024 |
| ORBIMED ADVISORS LLC | 3.55% | 0.82% | 2,861,801 | -536,266 | -15.78% | 41,381,642 | Jun 30, 2024 |
| CARLYLE GROUP INC. | 3.04% | 3.37% | 2,457,500 | - | - | 35,510,875 | Jun 30, 2024 |
| PERCEPTIVE ADVISORS LLC | 3.02% | 0.84% | 2,433,725 | -1,327,851 | -35.30% | 35,191,664 | Jun 30, 2024 |
| FEDERATED HERMES, INC. | 2.68% | 0.07% | 2,163,600 | -95,000 | -4.21% | 31,285,656,000 | Jun 30, 2024 |
| OCTAGON CAPITAL ADVISORS LP | 2.35% | 4.31% | 1,895,200 | -473,800 | -20.00% | 27,404,592 | Jun 30, 2024 |
| CALIGAN PARTNERS LP | 2.28% | 6.23% | 1,843,756 | 547,309 | 42.22% | 26,660,712 | Jun 30, 2024 |
| WELLINGTON MANAGEMENT GROUP LLP | 1.95% | 0.00% | 1,571,360 | -2,338,106 | -59.81% | 22,721,867 | Jun 30, 2024 |
| BELLEVUE GROUP AG | 1.41% | 0.27% | 1,134,229 | -5,066 | -0.44% | 16,400,951 | Jun 30, 2024 |
| JENNISON ASSOCIATES LLC | 1.40% | 0.01% | 1,128,032 | -465,801 | -29.23% | 16,311,342 | Jun 30, 2024 |
| AISLING CAPITAL MANAGEMENT LP | 1.38% | 6.98% | 1,115,352 | - | - | 16,127,990 | Jun 30, 2024 |
| JANUS HENDERSON GROUP PLC | 1.35% | 0.01% | 1,092,042 | -939,952 | -46.26% | 15,790,927 | Jun 30, 2024 |
| HOOD RIVER CAPITAL MANAGEMENT LLC | 1.32% | 0.32% | 1,062,456 | 74,700 | 7.56% | 15,363,114 | Jun 30, 2024 |
| LAURION CAPITAL MANAGEMENT LP | 1.30% | 0.18% | 1,050,842 | 168,802 | 19.14% | 15,195,175 | Jun 30, 2024 |
| PRICE T ROWE ASSOCIATES INC /MD/ | 1.18% | 0.00% | 949,375 | 949,375 | 100.00% | 13,728,000 | Jun 30, 2024 |
Verona Pharma's largest institutional shareholder is RA CAPITAL MANAGEMENT, L.P., holding 9.46% of the company's total share outstanding, currently valued at $110.37M. The top 10 institutional shareholders own together 45.95% of the company.
Institutional Shareholders by % of Total Assets
| Name | % Total Shares | % Total Assets | Current Shares | Change Amount | Change % | Market Value | Date |
|---|---|---|---|---|---|---|---|
| AISLING CAPITAL MANAGEMENT LP | 1.38% | 6.98% | 1,115,352 | - | - | 16,127,990 | Jun 30, 2024 |
| CALIGAN PARTNERS LP | 2.28% | 6.23% | 1,843,756 | 547,309 | 42.22% | 26,660,712 | Jun 30, 2024 |
| NEA MANAGEMENT COMPANY, LLC | 6.92% | 6.08% | 5,584,753 | 476,190 | 9.32% | 80,755,528 | Jun 30, 2024 |
| ALERCE INVESTMENT MANAGEMENT, L.P. | 0.26% | 6.04% | 213,000 | 213,000 | 100.00% | 3,079,980 | Jun 30, 2024 |
| VIVO CAPITAL, LLC | 4.40% | 4.74% | 3,549,758 | -60,419 | -1.67% | 51,329,501 | Jun 30, 2024 |
| OCTAGON CAPITAL ADVISORS LP | 2.35% | 4.31% | 1,895,200 | -473,800 | -20.00% | 27,404,592 | Jun 30, 2024 |
| CARLYLE GROUP INC. | 3.04% | 3.37% | 2,457,500 | - | - | 35,510,875 | Jun 30, 2024 |
| ROSALIND ADVISORS, INC. | 0.31% | 2.78% | 250,000 | - | - | 3,615,000 | Jun 30, 2024 |
| FRAZIER LIFE SCIENCES MANAGEMENT, L.P. | 4.11% | 2.24% | 3,314,349 | 300,000 | 9.95% | 47,925,487 | Jun 30, 2024 |
| KNOLL CAPITAL MANAGEMENT, LLC | 0.25% | 1.95% | 200,000 | - | - | 2,892,000 | Jun 30, 2024 |
| DEEP TRACK CAPITAL, LP | 4.96% | 1.73% | 4,000,000 | 812,585 | 25.49% | 57,840,000 | Jun 30, 2024 |
| RA CAPITAL MANAGEMENT, L.P. | 9.46% | 1.46% | 7,632,646 | 1,314,656 | 20.81% | 110,368,061 | Jun 30, 2024 |
| 1492 CAPITAL MANAGEMENT LLC | 0.20% | 1.34% | 163,647 | -616 | -0.38% | 2,366,336 | Jun 30, 2024 |
| KNOTT DAVID M JR | 0.25% | 1.17% | 203,000 | 88,000 | 76.52% | 2,935,000 | Jun 30, 2024 |
| AFFINITY ASSET ADVISORS, LLC | 0.87% | 1.17% | 700,000 | -117,833 | -14.41% | 10,122,000 | Jun 30, 2024 |
| PARKMAN HEALTHCARE PARTNERS LLC | 0.74% | 1.15% | 595,389 | 65,869 | 12.44% | 8,609,325 | Jun 30, 2024 |
| SAMSARA BIOCAPITAL, LLC | 0.43% | 1.05% | 347,500 | - | - | 5,024,850 | Jun 30, 2024 |
| SILVERARC CAPITAL MANAGEMENT, LLC | 0.38% | 1.04% | 304,633 | 167,919 | 122.83% | 4,404,993 | Jun 30, 2024 |
| MAVERICK CAPITAL LTD | 3.83% | 0.85% | 3,092,807 | 1,316,998 | 74.16% | 44,721,989 | Jun 30, 2024 |
| PERCEPTIVE ADVISORS LLC | 3.02% | 0.84% | 2,433,725 | -1,327,851 | -35.30% | 35,191,664 | Jun 30, 2024 |
The largest Verona Pharma shareholder by % of total assets is AISLING CAPITAL MANAGEMENT LP. The company owns 1.12M shares of Verona Pharma (VRNA), representing 6.98% of its total assets.
Institutional Buyers
| Name | % Total Shares | % Total Assets | Current Shares | Change Amount | Change % | Market Value | Date |
|---|---|---|---|---|---|---|---|
| MAVERICK CAPITAL LTD | 3.83% | 0.85% | 3,092,807 | 1,316,998 | 74.16% | 44,721,989 | Jun 30, 2024 |
| RA CAPITAL MANAGEMENT, L.P. | 9.46% | 1.46% | 7,632,646 | 1,314,656 | 20.81% | 110,368,061 | Jun 30, 2024 |
| PRICE T ROWE ASSOCIATES INC /MD/ | 1.18% | 0.00% | 949,375 | 949,375 | 100.00% | 13,728,000 | Jun 30, 2024 |
| DEEP TRACK CAPITAL, LP | 4.96% | 1.73% | 4,000,000 | 812,585 | 25.49% | 57,840,000 | Jun 30, 2024 |
| CANDRIAM S.C.A. | 0.96% | 0.07% | 772,997 | 772,997 | 100.00% | 11,177,015 | Jun 30, 2024 |
| PARADIGM BIOCAPITAL ADVISORS LP | 0.89% | 0.40% | 721,087 | 721,087 | 100.00% | 10,426,918 | Jun 30, 2024 |
| CALIGAN PARTNERS LP | 2.28% | 6.23% | 1,843,756 | 547,309 | 42.22% | 26,660,712 | Jun 30, 2024 |
| MORGAN STANLEY | 1.07% | 0.00% | 864,031 | 530,859 | 159.33% | 12,493,888 | Jun 30, 2024 |
| BANK OF AMERICA CORP /DE/ | 0.76% | 0.00% | 611,018 | 482,619 | 375.87% | 8,835,320 | Jun 30, 2024 |
| NEA MANAGEMENT COMPANY, LLC | 6.92% | 6.08% | 5,584,753 | 476,190 | 9.32% | 80,755,528 | Jun 30, 2024 |
| AMERICAN CENTURY COMPANIES INC | 1.09% | 0.01% | 878,043 | 317,184 | 56.55% | 12,696,522 | Jun 30, 2024 |
| LEGAL & GENERAL GROUP PLC | 0.48% | 0.00% | 384,208 | 304,635 | 382.84% | 5,555,647 | Jun 30, 2024 |
| FRAZIER LIFE SCIENCES MANAGEMENT, L.P. | 4.11% | 2.24% | 3,314,349 | 300,000 | 9.95% | 47,925,487 | Jun 30, 2024 |
| RICE HALL JAMES & ASSOCIATES, LLC | 1.16% | 0.81% | 939,576 | 263,819 | 39.04% | 13,586,269 | Jun 30, 2024 |
| BOOTHBAY FUND MANAGEMENT, LLC | 1.06% | 0.29% | 855,398 | 216,280 | 33.84% | 12,369,055 | Jun 30, 2024 |
| KENNEDY CAPITAL MANAGEMENT LLC | 0.42% | 0.10% | 337,535 | 214,320 | 173.94% | 4,880,756 | Jun 30, 2024 |
| ALERCE INVESTMENT MANAGEMENT, L.P. | 0.26% | 6.04% | 213,000 | 213,000 | 100.00% | 3,079,980 | Jun 30, 2024 |
| LAURION CAPITAL MANAGEMENT LP | 1.30% | 0.18% | 1,050,842 | 168,802 | 19.14% | 15,195,175 | Jun 30, 2024 |
| SILVERARC CAPITAL MANAGEMENT, LLC | 0.38% | 1.04% | 304,633 | 167,919 | 122.83% | 4,404,993 | Jun 30, 2024 |
| JUMP FINANCIAL, LLC | 0.21% | 0.05% | 168,438 | 153,709 | 1043.58% | 2,435,614 | Jun 30, 2024 |
As of Jun 30 2024, Verona Pharma's largest institutional buyer is MAVERICK CAPITAL LTD. The company purchased 1.32M stocks of VRNA, valued at $44.72M.
Institutional Sellers
| Name | % Total Shares | % Total Assets | Current Shares | Change Amount | Change % | Market Value | Date |
|---|---|---|---|---|---|---|---|
| WELLINGTON MANAGEMENT GROUP LLP | 1.95% | 0.00% | 1,571,360 | -2,338,106 | -59.81% | 22,721,867 | Jun 30, 2024 |
| EVENTIDE ASSET MANAGEMENT, LLC | 0.65% | 0.13% | 527,781 | -1,659,739 | -75.87% | 7,631,713 | Jun 30, 2024 |
| PERCEPTIVE ADVISORS LLC | 3.02% | 0.84% | 2,433,725 | -1,327,851 | -35.30% | 35,191,664 | Jun 30, 2024 |
| FMR LLC | 0.89% | 0.00% | 719,691 | -1,011,662 | -58.43% | 10,406,732 | Jun 30, 2024 |
| FIRST TURN MANAGEMENT, LLC | - | - | - | -973,130 | -100.00% | - | Jun 30, 2024 |
| JANUS HENDERSON GROUP PLC | 1.35% | 0.01% | 1,092,042 | -939,952 | -46.26% | 15,790,927 | Jun 30, 2024 |
| ALLY BRIDGE GROUP (NY) LLC | - | - | - | -736,738 | -100.00% | - | Jun 30, 2024 |
| ORBIMED ADVISORS LLC | 3.55% | 0.82% | 2,861,801 | -536,266 | -15.78% | 41,381,642 | Jun 30, 2024 |
| OCTAGON CAPITAL ADVISORS LP | 2.35% | 4.31% | 1,895,200 | -473,800 | -20.00% | 27,404,592 | Jun 30, 2024 |
| JENNISON ASSOCIATES LLC | 1.40% | 0.01% | 1,128,032 | -465,801 | -29.23% | 16,311,342 | Jun 30, 2024 |
| WOODLINE PARTNERS LP | 0.62% | 0.07% | 501,198 | -338,569 | -40.32% | 7,247,323 | Jun 30, 2024 |
| AXA S.A. | - | - | - | -277,784 | -100.00% | - | Jun 30, 2024 |
| SUPERSTRING CAPITAL MANAGEMENT LP | - | - | - | -259,383 | -100.00% | - | Jun 30, 2024 |
| IKARIAN CAPITAL, LLC | 0.25% | 0.51% | 201,116 | -174,194 | -46.41% | 2,908,138 | Jun 30, 2024 |
| TWO SIGMA INVESTMENTS, LP | 0.02% | 0.00% | 15,797 | -126,017 | -88.86% | 228,425 | Jun 30, 2024 |
| AFFINITY ASSET ADVISORS, LLC | 0.87% | 1.17% | 700,000 | -117,833 | -14.41% | 10,122,000 | Jun 30, 2024 |
| POLAR ASSET MANAGEMENT PARTNERS INC. | - | - | - | -96,500 | -100.00% | - | Jun 30, 2024 |
| FEDERATED HERMES, INC. | 2.68% | 0.07% | 2,163,600 | -95,000 | -4.21% | 31,285,656,000 | Jun 30, 2024 |
| NEUBERGER BERMAN GROUP LLC | 0.18% | 0.00% | 141,494 | -72,737 | -33.95% | 2,046,004 | Jun 30, 2024 |
| VIVO CAPITAL, LLC | 4.40% | 4.74% | 3,549,758 | -60,419 | -1.67% | 51,329,501 | Jun 30, 2024 |
As of Jun 30 2024, Verona Pharma's biggest institutional seller is WELLINGTON MANAGEMENT GROUP LLP. The company sold -2.34M shares of VRNA, valued at $22.72M.
Institutional New positions
| Name | % Total Shares | % Total Assets | Current Shares | Change Amount | Change % | Market Value | Date |
|---|---|---|---|---|---|---|---|
| PRICE T ROWE ASSOCIATES INC /MD/ | 1.18% | 0.00% | 949,375 | 949,375 | 100.00% | 13,728,000 | Jun 30, 2024 |
| CANDRIAM S.C.A. | 0.96% | 0.07% | 772,997 | 772,997 | 100.00% | 11,177,015 | Jun 30, 2024 |
| PARADIGM BIOCAPITAL ADVISORS LP | 0.89% | 0.40% | 721,087 | 721,087 | 100.00% | 10,426,918 | Jun 30, 2024 |
| ALERCE INVESTMENT MANAGEMENT, L.P. | 0.26% | 6.04% | 213,000 | 213,000 | 100.00% | 3,079,980 | Jun 30, 2024 |
| CAPTION MANAGEMENT, LLC | 0.17% | 0.03% | 140,000 | 140,000 | 100.00% | 2,024,400 | Jun 30, 2024 |
| TD ASSET MANAGEMENT INC | 0.15% | 0.00% | 121,600 | 121,600 | 100.00% | 1,758,336 | Jun 30, 2024 |
| D. E. SHAW & CO., INC. | 0.09% | 0.00% | 75,000 | 75,000 | 100.00% | 1,084,500 | Jun 30, 2024 |
| AMI ASSET MANAGEMENT CORP | 0.09% | 0.05% | 70,000 | 70,000 | 100.00% | 1,012,193 | Jun 30, 2024 |
| MANUFACTURERS LIFE INSURANCE COMPANY, THE | 0.07% | 0.00% | 59,418 | 59,418 | 100.00% | 859,184 | Jun 30, 2024 |
| TAIKANG ASSET MANAGEMENT (HONG KONG) CO LTD | 0.06% | 0.11% | 50,000 | 50,000 | 100.00% | 723,000 | Jun 30, 2024 |
| RESOLUTE CAPITAL ASSET PARTNERS LLC | 0.06% | 0.42% | 50,000 | 50,000 | 100.00% | 723,000 | Jun 30, 2024 |
| UBS OCONNOR LLC | 0.05% | 0.00% | 40,000 | 40,000 | 100.00% | 5,000 | Jun 30, 2024 |
| RENAISSANCE TECHNOLOGIES LLC | 0.04% | 0.00% | 31,044 | 31,044 | 100.00% | 448,896 | Jun 30, 2024 |
| CLEARSTEAD ADVISORS, LLC | 0.03% | 0.01% | 23,000 | 23,000 | 100.00% | 332,580 | Jun 30, 2024 |
| BOOTHBAY FUND MANAGEMENT, LLC | 0.03% | 0.01% | 22,300 | 22,300 | 100.00% | 322,458 | Jun 30, 2024 |
| VERUS CAPITAL PARTNERS, LLC | 0.02% | 0.02% | 17,385 | 17,385 | 100.00% | 251,391 | Jun 30, 2024 |
| AMERIPRISE FINANCIAL INC | 0.02% | 0.00% | 13,159 | 13,159 | 100.00% | 190,279 | Jun 30, 2024 |
| BAROMETER CAPITAL MANAGEMENT INC. | 0.01% | 0.06% | 11,400 | 11,400 | 100.00% | 164,844 | Jun 30, 2024 |
| LPL FINANCIAL LLC | 0.01% | 0.00% | 10,181 | 10,181 | 100.00% | 147,217 | Jun 30, 2024 |
| NOMURA HOLDINGS INC | 0.01% | 0.00% | 10,000 | 10,000 | 100.00% | 144,600 | Jun 30, 2024 |
| NEWEDGE ADVISORS, LLC | 0.01% | 0.00% | 7,300 | 7,300 | 100.00% | 105,558 | Jun 30, 2024 |
| EMC CAPITAL MANAGEMENT | 0.00% | 0.02% | 2,500 | 2,500 | 100.00% | 38,000 | Jun 30, 2024 |
| MIRAE ASSET GLOBAL INVESTMENTS CO., LTD. | 0.00% | 0.00% | 2,081 | 2,081 | 100.00% | 32,131 | Jun 30, 2024 |
| CWM, LLC | 0.00% | 0.00% | 2,000 | 2,000 | 100.00% | 29,000 | Jun 30, 2024 |
| HIGHTOWER ADVISORS, LLC | 0.00% | - | 500 | 500 | 100.00% | 325 | Jun 30, 2024 |
| REDWOOD WEALTH MANAGEMENT GROUP, LLC | 0.00% | 0.00% | 410 | 410 | 100.00% | 5,929 | Jun 30, 2024 |
| NATIONAL BANK OF CANADA /FI/ | 0.00% | - | 150 | 150 | 100.00% | 2,314 | Jun 30, 2024 |
| NAPLES MONEY MANAGEMENT LLC | 0.00% | 0.00% | 100 | 100 | 100.00% | 1,551 | Jun 30, 2024 |
Verona Pharma's largest new institutional shareholder by number of shares is PRICE T ROWE ASSOCIATES INC /MD/, purchased 949.38K shares, valued at $13.73M, as of undefined.
Institutional Sold Out
| Name | % Total Shares | % Total Assets | Current Shares | Change Amount | Change % | Market Value | Date |
|---|---|---|---|---|---|---|---|
| FIRST TURN MANAGEMENT, LLC | - | - | - | -973,130 | -100.00% | - | Jun 30, 2024 |
| ALLY BRIDGE GROUP (NY) LLC | - | - | - | -736,738 | -100.00% | - | Jun 30, 2024 |
| AXA S.A. | - | - | - | -277,784 | -100.00% | - | Jun 30, 2024 |
| SUPERSTRING CAPITAL MANAGEMENT LP | - | - | - | -259,383 | -100.00% | - | Jun 30, 2024 |
| POLAR ASSET MANAGEMENT PARTNERS INC. | - | - | - | -96,500 | -100.00% | - | Jun 30, 2024 |
| UBS OCONNOR LLC | - | - | - | -36,305 | -100.00% | - | Jun 30, 2024 |
| BANK OF NEW YORK MELLON CORP | - | - | - | -29,676 | -100.00% | - | Jun 30, 2024 |
| CAPSTONE INVESTMENT ADVISORS, LLC | - | - | - | -25,616 | -100.00% | - | Jun 30, 2024 |
| VIRTU FINANCIAL LLC | - | - | - | -23,180 | -100.00% | - | Jun 30, 2024 |
| CUBIST SYSTEMATIC STRATEGIES, LLC | - | - | - | -13,682 | -100.00% | - | Jun 30, 2024 |
| QUANTBOT TECHNOLOGIES LP | - | - | - | -2,458 | -100.00% | - | Jun 30, 2024 |
| ENTRYPOINT CAPITAL, LLC | - | - | - | -1,175 | -100.00% | - | Jun 30, 2024 |
| CORECAP ADVISORS, LLC | - | - | - | -657 | -100.00% | - | Jun 30, 2024 |
| EVERSOURCE WEALTH ADVISORS, LLC | - | - | - | -295 | -100.00% | - | Jun 30, 2024 |
| ZURCHER KANTONALBANK (ZURICH CANTONALBANK) | - | - | - | -2 | -100.00% | - | Jun 30, 2024 |
Verona Pharma's largest sold out institutional shareholder by shares sold is FIRST TURN MANAGEMENT, LLC, sold -0.97M shares, valued at -, as of undefined.
Verona Pharma Mutual Fund Holders
| Name | % Total Assets | Total Shares | Change Amount | Change % | Date |
|---|---|---|---|---|---|
| Manager Directed Portfolios | 2.41% | 395,153 | - | - | Jan 31, 2024 |
| TEKLA LIFE SCIENCES INVESTORS | 0.67% | 315,800 | - | - | Mar 31, 2024 |
| Tekla World Healthcare Fund | 0.36% | 436,105 | - | - | Mar 31, 2024 |
| PRUDENTIAL SECTOR FUNDS, INC. | 0.34% | 699,240 | - | - | Feb 29, 2024 |
| Federated Hermes Equity Funds | 0.13% | 2,459,364 | - | - | Jan 31, 2024 |
| PRUDENTIAL JENNISON BLEND FUND, INC. | 0.08% | 46,882 | 6,032 | 14.77% | Feb 29, 2024 |
| AMERICAN CENTURY MUTUAL FUNDS, INC. | 0.05% | 489,671 | 112,434 | 29.80% | Jan 31, 2024 |
| FIDELITY ADVISOR SERIES VII | 0.05% | 400,000 | -305,367 | -43.29% | Jan 31, 2024 |
| VARIABLE INSURANCE PRODUCTS FUND IV | 0.03% | 85,000 | - | - | Mar 31, 2024 |
| FIDELITY CAPITAL TRUST | 0.02% | 247,591 | - | - | Jan 31, 2024 |
| FIDELITY SELECT PORTFOLIOS | 0.02% | 1,071,101 | -868,400 | -44.77% | Feb 29, 2024 |
| BNY Mellon Strategic Funds, Inc. | 0.01% | 28,474 | 996 | 3.62% | Feb 29, 2024 |
| NEUBERGER BERMAN EQUITY FUNDS | 0.01% | 96,259 | 96,259 | - | Feb 29, 2024 |
| FIDELITY SECURITIES FUND | 0.01% | 898,557 | - | - | Jan 31, 2024 |
| FIDELITY CONTRAFUND | 0.01% | 548,878 | - | - | Mar 31, 2024 |
| FIDELITY COMMONWEALTH TRUST | 0.01% | 25,324 | 4,314 | 20.53% | Feb 29, 2024 |
| FEDERATED HERMES INSURANCE SERIES | 0.01% | 29,100 | -5,066 | -14.83% | Mar 31, 2024 |
| ALPS ETF Trust | 0.00% | 58,412 | 2,272 | 4.05% | Feb 29, 2024 |
| CLEARWATER INVESTMENT TRUST | 0.00% | 33,045 | 12,782 | 63.08% | Mar 28, 2024 |
| HARTFORD SERIES FUND INC | 0.00% | 130,757 | -4,895 | -3.61% | Mar 31, 2024 |
| Fidelity Central Investment Portfolios LLC | 0.00% | 150,000 | - | - | Feb 29, 2024 |
| Guardian Variable Products Trust | 0.00% | 45,700 | -2,000 | -4.19% | Mar 31, 2024 |
| VARIABLE INSURANCE PRODUCTS FUND II | 0.00% | 26,400 | - | - | Mar 31, 2024 |
| MML SERIES INVESTMENT FUND | 0.00% | 19,033 | - | - | Dec 31, 2023 |
| VARIABLE INSURANCE PRODUCTS FUND | 0.00% | 40,000 | - | - | Mar 31, 2024 |
| FIDELITY ADVISOR SERIES I | 0.00% | 325,600 | - | - | Feb 29, 2024 |
| JANUS INVESTMENT FUND | 0.00% | 498,426 | - | - | Dec 31, 2023 |
| NATIONWIDE MUTUAL FUNDS | 0.00% | 150,224 | -30,535 | -16.89% | Jan 31, 2024 |
| PENN SERIES FUNDS INC | 0.00% | 16,749 | - | - | Mar 28, 2024 |
| JOHN HANCOCK INVESTMENT TRUST | 0.00% | 48,000 | 12,695 | 35.96% | Jan 31, 2024 |
| MUTUAL FUND SERIES TRUST | 0.00% | 2,243,520 | 809,739 | 56.48% | Mar 31, 2024 |
| CALAMOS INVESTMENT TRUST/IL | 0.00% | 48,880 | 48,880 | - | Jan 31, 2024 |
| Advisors' Inner Circle Fund III | 0.00% | 41,786 | - | - | Jan 31, 2024 |
| AMERICAN CENTURY STRATEGIC ASSET ALLOCATIONS INC | 0.00% | 4,013 | 899 | 28.87% | Jan 31, 2024 |
| MAINSTAY VP FUNDS TRUST | 0.00% | 33,756 | -3,713 | -9.91% | Mar 31, 2024 |
| VALIC Co I | 0.00% | 58,820 | -10,797 | -15.51% | Feb 29, 2024 |
| FIDELITY CONCORD STREET TRUST | 0.00% | 40,048 | - | - | Feb 29, 2024 |
| Goldman Sachs ETF Trust | 0.00% | 17,557 | -1,460 | -7.68% | Feb 29, 2024 |
| SPDR INDEX SHARES FUNDS | 0.00% | 33,572 | -4,788 | -12.48% | Mar 31, 2024 |
| Fidelity Rutland Square Trust II | 0.00% | 152,790 | 49,870 | 48.46% | Feb 29, 2024 |
| FIDELITY COVINGTON TRUST | 0.00% | 1,882 | 266 | 16.46% | Jan 31, 2024 |
| MASSMUTUAL SELECT FUNDS | 0.00% | 67,058 | - | - | Dec 31, 2023 |
| Series Portfolios Trust | 0.00% | 365 | 365 | - | Jan 31, 2024 |
| HARTFORD MUTUAL FUNDS INC/CT | 0.00% | 364,917 | -13,070 | -3.46% | Jan 31, 2024 |
| JOHN HANCOCK VARIABLE INSURANCE TRUST | 0.00% | 70,557 | -957 | -1.34% | Mar 31, 2024 |
| TRUST FOR PROFESSIONAL MANAGERS | 0.00% | 9,216 | 6,561 | 247.12% | Feb 29, 2024 |
| PACE SELECT ADVISORS TRUST | 0.00% | 7,556 | 7,556 | - | Jan 31, 2024 |
| Legg Mason Global Asset Management Trust | 0.00% | 164,700 | 164,700 | - | Jan 31, 2024 |
| iSHARES TRUST | 0.00% | 344,841 | 13,629 | 4.11% | Mar 31, 2024 |
| PROSHARES TRUST | 0.00% | 4,987 | 717 | 16.79% | Feb 29, 2024 |
| Investment Managers Series Trust II | 0.00% | 176 | - | - | Mar 31, 2024 |
| Blackstone Alternative Investment Funds | 0.00% | 1,100 | -700 | -38.89% | Mar 31, 2024 |
| USAA MUTUAL FUNDS TRUST | 0.00% | 1,971 | -1,751 | -47.04% | Jan 31, 2024 |
| PRUDENTIAL INVESTMENT PORTFOLIOS 2 | 0.00% | 1,525 | 300 | 24.49% | Jan 31, 2024 |
| Invesco Exchange-Traded Fund Trust II | 0.00% | 1,775 | 602 | 51.32% | Feb 29, 2024 |
| Franklin Alternative Strategies Funds | 0.00% | 1,553 | - | - | Feb 29, 2024 |
| PRINCIPAL FUNDS, INC. | 0.00% | 1,039 | -568 | -35.35% | Feb 29, 2024 |
Verona Pharma's largest mutual fund holder by % of total assets is "Manager Directed Portfolios", owning 395.15K shares, compromising 2.41% of its total assets.
Verona Pharma Institutional Ownership Trends
Institutional Holdings Trend
| Date | Holdings | Change % |
|---|---|---|
| 30 Jun, 24 | 129 | 10.26% |
| 31 Mar, 24 | 117 | -4.88% |
| 31 Dec, 23 | 123 | 13.89% |
| 30 Sep, 23 | 108 | - |
| 30 Jun, 23 | 108 | 10.20% |
| 31 Mar, 23 | 98 | -3.92% |
| 31 Dec, 22 | 102 | 41.67% |
| 30 Sep, 22 | 72 | 84.62% |
| 30 Jun, 22 | 39 | - |
| 31 Mar, 22 | 39 | -11.36% |
| 31 Dec, 21 | 44 | 15.79% |
| 30 Sep, 21 | 38 | 8.57% |
| 30 Jun, 21 | 35 | -5.41% |
| 31 Mar, 21 | 37 | 2.78% |
| 31 Dec, 20 | 36 | 38.46% |
| 30 Sep, 20 | 26 | 44.44% |
| 30 Jun, 20 | 18 | 28.57% |
| 31 Mar, 20 | 14 | - |
| 31 Dec, 19 | 14 | 7.69% |
| 30 Sep, 19 | 13 | -23.53% |
| 30 Jun, 19 | 17 | - |
| 31 Mar, 19 | 17 | - |
| 31 Dec, 18 | 17 | 21.43% |
| 30 Sep, 18 | 14 | 7.69% |
| 30 Jun, 18 | 13 | -7.14% |
| 31 Mar, 18 | 14 | 40.00% |
| 31 Dec, 17 | 10 | 11.11% |
| 30 Sep, 17 | 9 | - |
| 30 Jun, 17 | 9 | - |
As of 30 Jun 24, 129 institutions are holding Verona Pharma's shares, representing an increase of 10.26% compared to the previous quarter.
Shares Outstanding Trend
| Date | Shares Outstanding | Change % |
|---|---|---|
| 30 Jun, 24 | 65,829,213 | -1.15% |
| 31 Mar, 24 | 66,592,785 | -1.29% |
| 31 Dec, 23 | 67,465,963 | 3.39% |
| 30 Sep, 23 | 65,253,179 | 3.82% |
| 30 Jun, 23 | 62,854,386 | 4.12% |
| 31 Mar, 23 | 60,365,485 | 10.87% |
| 31 Dec, 22 | 54,447,167 | 4.53% |
| 30 Sep, 22 | 52,089,541 | 48.41% |
| 30 Jun, 22 | 35,099,251 | -3.69% |
| 31 Mar, 22 | 36,443,884 | -1.33% |
| 31 Dec, 21 | 36,936,239 | -0.22% |
| 30 Sep, 21 | 37,018,796 | 0.87% |
| 30 Jun, 21 | 36,699,886 | 0.46% |
| 31 Mar, 21 | 36,531,198 | 2.74% |
| 31 Dec, 20 | 35,557,982 | 5.76% |
| 30 Sep, 20 | 33,620,218 | 368.67% |
| 30 Jun, 20 | 7,173,525 | 2.71% |
| 31 Mar, 20 | 6,984,029 | 19.38% |
| 31 Dec, 19 | 5,850,121 | -0.21% |
| 30 Sep, 19 | 5,862,453 | -20.44% |
| 30 Jun, 19 | 7,368,489 | -0.17% |
| 31 Mar, 19 | 7,381,315 | -12.20% |
| 31 Dec, 18 | 8,407,168 | 13.97% |
| 30 Sep, 18 | 7,376,882 | 13.65% |
| 30 Jun, 18 | 6,490,956 | -1.39% |
| 31 Mar, 18 | 6,582,136 | -1.43% |
| 31 Dec, 17 | 6,677,932 | 26.48% |
| 30 Sep, 17 | 5,279,998 | 33.53% |
| 30 Jun, 17 | 3,954,155 | - |
Verona Pharma (VRNA) has 65.83M shares outstanding as of 30 Jun 24, down -1.15% compared to the previous quarter.
Institutional Ownership Trend
| Date | Ownership % | Change % |
|---|---|---|
| 30 Jun, 24 | 81.56% | 1.16% |
| 31 Mar, 24 | 84.01% | 75.18% |
| 31 Dec, 23 | 10.57% | 0.16% |
| 30 Sep, 23 | 82.28% | 1.26% |
| 30 Jun, 23 | 80.91% | 1.34% |
| 31 Mar, 23 | 77.71% | 0.92% |
| 31 Dec, 22 | 92.05% | 1.57% |
| 30 Sep, 22 | 76.58% | 2.28% |
| 30 Jun, 22 | 57.92% | 1.58% |
| 31 Mar, 22 | 60.50% | 1.55% |
| 31 Dec, 21 | 62.45% | 1.61% |
| 30 Sep, 21 | 62.30% | 1.60% |
| 30 Jun, 21 | 62.36% | 1.61% |
| 31 Mar, 21 | 62.25% | 0.53% |
| 31 Dec, 20 | 108.19% | 1.78% |
| 30 Sep, 20 | 78.00% | 28.16% |
| 30 Jun, 20 | 16.64% | 6.34% |
| 31 Mar, 20 | 16.20% | 8.80% |
| 31 Dec, 19 | 13.57% | 7.34% |
| 30 Sep, 19 | 13.60% | 4.65% |
| 30 Jun, 19 | 17.10% | 5.83% |
| 31 Mar, 19 | 17.13% | 4.50% |
| 31 Dec, 18 | 19.51% | 6.66% |
| 30 Sep, 18 | 17.12% | 7.55% |
| 30 Jun, 18 | 15.06% | 6.46% |
| 31 Mar, 18 | 15.27% | 6.36% |
| 31 Dec, 17 | 15.49% | 10.32% |
| 30 Sep, 17 | 12.25% | 14.56% |
| 30 Jun, 17 | 9.17% | - |
As of 30 Jun 24, Verona Pharma is held by 81.56% institutional shareholders, representing a 1.16% growth compared to 31 Mar 24.
Institutional Increased Positions Trend
| Date | Increased Positions | Change % |
|---|---|---|
| 30 Jun, 24 | 68 | 15.25% |
| 31 Mar, 24 | 59 | -4.84% |
| 31 Dec, 23 | 62 | 34.78% |
| 30 Sep, 23 | 46 | -6.12% |
| 30 Jun, 23 | 49 | -15.52% |
| 31 Mar, 23 | 58 | 1.75% |
| 31 Dec, 22 | 57 | 7.55% |
| 30 Sep, 22 | 53 | 278.57% |
| 30 Jun, 22 | 14 | - |
| 31 Mar, 22 | 14 | -6.67% |
| 31 Dec, 21 | 15 | - |
| 30 Sep, 21 | 15 | 50.00% |
| 30 Jun, 21 | 10 | -28.57% |
| 31 Mar, 21 | 14 | -26.32% |
| 31 Dec, 20 | 19 | -9.52% |
| 30 Sep, 20 | 21 | 200.00% |
| 30 Jun, 20 | 7 | 75.00% |
| 31 Mar, 20 | 4 | -20.00% |
| 31 Dec, 19 | 5 | 150.00% |
| 30 Sep, 19 | 2 | 100.00% |
| 30 Jun, 19 | 1 | -80.00% |
| 31 Mar, 19 | 5 | - |
| 31 Dec, 18 | 5 | 150.00% |
| 30 Sep, 18 | 2 | - |
| 30 Jun, 18 | 2 | -71.43% |
| 31 Mar, 18 | 7 | 75.00% |
| 31 Dec, 17 | 4 | - |
| 30 Sep, 17 | 4 | -55.56% |
| 30 Jun, 17 | 9 | - |
68 institutional shareholders have increased their position in VRNA stock as of 30 Jun 24 compared to 59 in the previous quarter (a 15.25% increase).
Institutional Reduced Positions Trend
| Date | Reduced Positions | Change % |
|---|---|---|
| 30 Jun, 24 | 33 | 22.22% |
| 31 Mar, 24 | 27 | -6.90% |
| 31 Dec, 23 | 29 | -6.45% |
| 30 Sep, 23 | 31 | -3.13% |
| 30 Jun, 23 | 32 | 33.33% |
| 31 Mar, 23 | 24 | -11.11% |
| 31 Dec, 22 | 27 | 285.71% |
| 30 Sep, 22 | 7 | 75.00% |
| 30 Jun, 22 | 4 | - |
| 31 Mar, 22 | 4 | -50.00% |
| 31 Dec, 21 | 8 | 100.00% |
| 30 Sep, 21 | 4 | -20.00% |
| 30 Jun, 21 | 5 | -50.00% |
| 31 Mar, 21 | 10 | 233.33% |
| 31 Dec, 20 | 3 | - |
| 30 Sep, 20 | 3 | - |
| 30 Jun, 20 | - | -100.00% |
| 31 Mar, 20 | 4 | - |
| 31 Dec, 19 | - | -100.00% |
| 30 Sep, 19 | 2 | -50.00% |
| 30 Jun, 19 | 4 | 300.00% |
| 31 Mar, 19 | 1 | -50.00% |
| 31 Dec, 18 | 2 | - |
| 30 Sep, 18 | 2 | -33.33% |
| 30 Jun, 18 | 3 | 200.00% |
| 31 Mar, 18 | 1 | - |
| 31 Dec, 17 | 1 | - |
| 30 Sep, 17 | 1 | - |
| 30 Jun, 17 | - | - |
33 institutional shareholders have reduced their position in VRNA stock as of 30 Jun 24 compared to 27 in the previous quarter (a 22.22% increase).
All Institutional Ownership Trend Data
| Date | Holdings | Change % | Shares Outstanding | Change % | Ownership % | Change % | Increased Positions | Change % | Reduced Positions | Change % |
|---|---|---|---|---|---|---|---|---|---|---|
| 30 Jun, 24 | 129 | 10.26% | 65,829,213 | -1.15% | 81.56% | 1.16% | 68 | 15.25% | 33 | 22.22% |
| 31 Mar, 24 | 117 | -4.88% | 66,592,785 | -1.29% | 84.01% | 75.18% | 59 | -4.84% | 27 | -6.90% |
| 31 Dec, 23 | 123 | 13.89% | 67,465,963 | 3.39% | 10.57% | 0.16% | 62 | 34.78% | 29 | -6.45% |
| 30 Sep, 23 | 108 | - | 65,253,179 | 3.82% | 82.28% | 1.26% | 46 | -6.12% | 31 | -3.13% |
| 30 Jun, 23 | 108 | 10.20% | 62,854,386 | 4.12% | 80.91% | 1.34% | 49 | -15.52% | 32 | 33.33% |
| 31 Mar, 23 | 98 | -3.92% | 60,365,485 | 10.87% | 77.71% | 0.92% | 58 | 1.75% | 24 | -11.11% |
| 31 Dec, 22 | 102 | 41.67% | 54,447,167 | 4.53% | 92.05% | 1.57% | 57 | 7.55% | 27 | 285.71% |
| 30 Sep, 22 | 72 | 84.62% | 52,089,541 | 48.41% | 76.58% | 2.28% | 53 | 278.57% | 7 | 75.00% |
| 30 Jun, 22 | 39 | - | 35,099,251 | -3.69% | 57.92% | 1.58% | 14 | - | 4 | - |
| 31 Mar, 22 | 39 | -11.36% | 36,443,884 | -1.33% | 60.50% | 1.55% | 14 | -6.67% | 4 | -50.00% |
| 31 Dec, 21 | 44 | 15.79% | 36,936,239 | -0.22% | 62.45% | 1.61% | 15 | - | 8 | 100.00% |
| 30 Sep, 21 | 38 | 8.57% | 37,018,796 | 0.87% | 62.30% | 1.60% | 15 | 50.00% | 4 | -20.00% |
| 30 Jun, 21 | 35 | -5.41% | 36,699,886 | 0.46% | 62.36% | 1.61% | 10 | -28.57% | 5 | -50.00% |
| 31 Mar, 21 | 37 | 2.78% | 36,531,198 | 2.74% | 62.25% | 0.53% | 14 | -26.32% | 10 | 233.33% |
| 31 Dec, 20 | 36 | 38.46% | 35,557,982 | 5.76% | 108.19% | 1.78% | 19 | -9.52% | 3 | - |
| 30 Sep, 20 | 26 | 44.44% | 33,620,218 | 368.67% | 78.00% | 28.16% | 21 | 200.00% | 3 | - |
| 30 Jun, 20 | 18 | 28.57% | 7,173,525 | 2.71% | 16.64% | 6.34% | 7 | 75.00% | - | -100.00% |
| 31 Mar, 20 | 14 | - | 6,984,029 | 19.38% | 16.20% | 8.80% | 4 | -20.00% | 4 | - |
| 31 Dec, 19 | 14 | 7.69% | 5,850,121 | -0.21% | 13.57% | 7.34% | 5 | 150.00% | - | -100.00% |
| 30 Sep, 19 | 13 | -23.53% | 5,862,453 | -20.44% | 13.60% | 4.65% | 2 | 100.00% | 2 | -50.00% |
| 30 Jun, 19 | 17 | - | 7,368,489 | -0.17% | 17.10% | 5.83% | 1 | -80.00% | 4 | 300.00% |
| 31 Mar, 19 | 17 | - | 7,381,315 | -12.20% | 17.13% | 4.50% | 5 | - | 1 | -50.00% |
| 31 Dec, 18 | 17 | 21.43% | 8,407,168 | 13.97% | 19.51% | 6.66% | 5 | 150.00% | 2 | - |
| 30 Sep, 18 | 14 | 7.69% | 7,376,882 | 13.65% | 17.12% | 7.55% | 2 | - | 2 | -33.33% |
| 30 Jun, 18 | 13 | -7.14% | 6,490,956 | -1.39% | 15.06% | 6.46% | 2 | -71.43% | 3 | 200.00% |
| 31 Mar, 18 | 14 | 40.00% | 6,582,136 | -1.43% | 15.27% | 6.36% | 7 | 75.00% | 1 | - |
| 31 Dec, 17 | 10 | 11.11% | 6,677,932 | 26.48% | 15.49% | 10.32% | 4 | - | 1 | - |
| 30 Sep, 17 | 9 | - | 5,279,998 | 33.53% | 12.25% | 14.56% | 4 | -55.56% | 1 | - |
| 30 Jun, 17 | 9 | - | 3,954,155 | - | 9.17% | - | 9 | - | - | - |
Verona Pharma Insider Shareholders Trades
Open Market Insider Trades
Open Market Insider Buys
Insider Sells
All Insider Owners Trades
The last insider sell of Verona Pharma's stock was made by ZACCARDELLI DAVID on Aug 14 2024, selling 1,600 shares at $3.13 per share (valued at $5.01K). The last insider buy of VRNA was made by EBSWORTH DAVID R on Aug 14 2024, buying 36,000 shares at $2.87 per share (worth $103.32K).
Verona Pharma Insider Ownership Trends
All Insider Trades Trend
| Date | Buy | Sell | Buy/Sell Ratio |
|---|---|---|---|
| Q3 2024 | 4 | 12 | 33.33% |
| Q2 2024 | 10 | 4 | 250.00% |
| Q1 2024 | 2 | 6 | 33.33% |
| Q4 2023 | 7 | 6 | 116.67% |
| Q3 2023 | 2 | 22 | 9.09% |
| Q2 2023 | 11 | 15 | 73.33% |
| Q1 2023 | 3 | 9 | 33.33% |
| Q4 2022 | 1 | 20 | 5.00% |
| Q3 2022 | 4 | 10 | 40.00% |
| Q2 2022 | 14 | 9 | 155.56% |
| Q1 2022 | 4 | 8 | 50.00% |
| Q4 2021 | 1 | 8 | 12.50% |
| Q3 2021 | 11 | 10 | 110.00% |
| Q2 2021 | - | 11 | - |
| Q1 2021 | 3 | 33 | 9.09% |
| Q2 2017 | - | 1 | - |
4 total buy trades, and 12 total sell trades (buy/sell ratio of 0.33%) were made by Verona Pharma's insiders, as of Q3 2024.
Open Market Insider Trades Trend
| Date | Buy | Sell | Buy/Sell Ratio |
|---|---|---|---|
| Q3 2024 | 1 | 6 | 16.67% |
| Q2 2024 | - | 1 | - |
| Q1 2024 | - | 1 | - |
| Q4 2023 | 2 | 1 | 200.00% |
| Q3 2023 | - | 21 | - |
| Q2 2023 | - | 13 | - |
| Q1 2023 | - | 5 | - |
| Q4 2022 | - | 16 | - |
| Q3 2022 | 2 | 5 | 40.00% |
| Q2 2022 | - | 4 | - |
| Q1 2022 | - | 3 | - |
| Q4 2021 | - | 3 | - |
| Q3 2021 | - | 4 | - |
| Q2 2021 | - | 9 | - |
| Q1 2021 | - | 8 | - |
| Q2 2017 | - | - | - |
As of Q3 2024, Insider owners conducted 1 open market buy trades and 6 open market sell trades of Verona Pharma's stocks.
Verona Pharma Peer Ownership
| Ticker | Company |
|---|---|
| AKRO | Akero Therapeutics, Inc. |
| XFOR | X4 Pharmaceuticals, Inc. |
| IDYA | IDEAYA Biosciences, Inc. |
| MREO | Mereo BioPharma Group plc |
| APLS | Apellis Pharmaceuticals, Inc. |
| DAWN | Day One Biopharmaceuticals, Inc. |
| VTYX | Ventyx Biosciences, Inc. |
| SNDX | Syndax Pharmaceuticals, Inc. |
| TERN | Terns Pharmaceuticals, Inc. |
| VKTX | Viking Therapeutics, Inc. |
| INZY | Inozyme Pharma, Inc. |
| MLTX | MoonLake Immunotherapeutics |
| ABOS | Acumen Pharmaceuticals, Inc. |
| PTGX | Protagonist Therapeutics, Inc. |
| MDGL | Madrigal Pharmaceuticals, Inc. |
| AMLX | Amylyx Pharmaceuticals, Inc. |
VRNA Ownership FAQ
Who Owns Verona Pharma?
Verona Pharma is owned by institutional shareholders (81.56%), insiders (3.90%), and public (14.54%). The largest institutional shareholder of Verona Pharma is RA CAPITAL MANAGEMENT, L.P. (9.46% of total shares) and the top mutual fund owner is Manager Directed Portfolios (2.41% of total shares).
Who are the major institutional shareholders of Verona Pharma?
Verona Pharma's major institutional shareholders are RA CAPITAL MANAGEMENT, L.P., NEA MANAGEMENT COMPANY, LLC, DEEP TRACK CAPITAL, LP, VIVO CAPITAL, LLC, and FRAZIER LIFE SCIENCES MANAGEMENT, L.P.. The top five shareholders own together 29.84% of the company's share outstanding.
How many Verona Pharma shareholders are there?
As of Jun 2024, there are 129 institutional shareholders of Verona Pharma.
What percentage of Verona Pharma is owned by RA CAPITAL MANAGEMENT, L.P?
RA CAPITAL MANAGEMENT, L.P owns 7.63M shares of Verona Pharma, representing 9.46% of the company's total shares outstanding, valued at $110.37M (as of Jun 2024).
What percentage of Verona Pharma is owned by NEA MANAGEMENT COMPANY, LLC?
As of Jun 2024, NEA MANAGEMENT COMPANY, LLC holds 5.58M shares of Verona Pharma (VRNA), compromising 6.92% of the company, valued at $80.76M.
What percentage of Verona Pharma is owned by DEEP TRACK CAPITAL, LP?
DEEP TRACK CAPITAL, LP is the third largest holder of Verona Pharma. The company owns 4M of the company's shares outstanding (worth $57.84M).